O'Shea D, Byrne M, Powell D
Mater Hospital, Dublin.
Ir Med J. 1990 Mar;83(1):25-7.
325 patients referred to an endocrine clinic with short stature were reviewed, 32 (9.8%) were above the third centile for height and maintained normal growth velocities, fourteen (4.3%) have not had assessment completed. Of 279 children in whom the cause of short stature was established, 140 (50%) had constitutional short stature/delayed puberty (CSS/DP). Seventy-three (26%) had idiopathic growth hormone deficiency (GHD), complete in 23, while 66 patients (34%) had short stature due to other causes. Girls presented earlier (mean age 11.9) than boys (mean age 13.3) and GHD patients earlier than CSS/DP patients with bimodal peaks at 12 and 16 years. Male CSS/DP patients reached their mid pubertal point later than normal at 16.06 +/- 1.19 years (p less than .05) while in GHD males the mid pubertal age was 16.6 years (p less than .05). In female patients with short stature no significant pubertal delay was observed. The average growth velocity of complete GHD patients pre treatment was 3.7 cms/year. Velocity rose to 6.2 cms/year on human growth hormone (HGH) extract and rose further to 8.1 cms/year on biosynthetic HGH. In partial GHD patients the average pre-treatment velocity of 4.3 cm/year rose to an average of 6.0 cm/yr on HGH extract and maintained this velocity on biosynthetic HGH.
对325名因身材矮小而转诊至内分泌诊所的患者进行了回顾性研究，其中32名（9.8%）身高高于第三百分位且生长速度正常，14名（4.3%）未完成评估。在279名已明确身材矮小原因的儿童中，140名（50%）患有体质性身材矮小/青春期发育延迟（CSS/DP）。73名（26%）患有特发性生长激素缺乏症（GHD），其中23名完全缺乏，而66名患者（34%）因其他原因身材矮小。女孩就诊时间早于男孩（平均年龄11.9岁对13.3岁），GHD患者早于CSS/DP患者，在12岁和16岁出现双峰。男性CSS/DP患者达到青春期中期的时间比正常晚，为16.06±1.19岁（p<0.05），而GHD男性的青春期中期年龄为16.6岁（p<0.05）。身材矮小的女性患者未观察到明显的青春期延迟。完全性GHD患者治疗前的平均生长速度为3.7厘米/年。使用人生长激素（HGH）提取物后速度升至6.2厘米/年，使用生物合成HGH后进一步升至8.1厘米/年。部分GHD患者治疗前的平均速度为4.3厘米/年，使用HGH提取物后平均升至6.0厘米/年，使用生物合成HGH后维持该速度。
